Zacks Investment Research on MSN
Johnson & Johnson (JNJ) is a trending stock: Facts to know before betting on it
Johnson & Johnson (JNJ) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...
Johnson & Johnson (NYSE:JNJ) is included among the 15 Best S&P 500 Dividend Stocks to Buy in 2026. Johnson & Johnson (NYSE:JNJ) posted its fourth-quarter 2025 earnings on January 21 and followed it up ...
Johnson & Johnson’s (NYSE: JNJ) stock price can continue to advance because its strategy to reinvigorate growth and widen margins is working. The plan centers on divesting underperforming healthcare ...
After a strong performance in 2025, Johnson & Johnson is starting the new year right.
Johnson & Johnson’s post-Kenvue shift boosts growth and free cash flow, with an elite balance sheet but mixed revisions.
The average one-year price target for Johnson & Johnson (NYSE:JNJ) has been revised to $204.02 / share. This is an increase of 10.96% from the prior estimate of $183.86 dated September 27, 2025. The ...
Johnson & Johnson (NYSE:JNJ) stock is down 1.2% to trade at $188.54 at last glance, brushing off an earnings and revenue beat for the third quarter. The pharma company also announced it will spin off ...
Johnson & Johnson (NYSE:JNJ) is included among the 15 Dividend Stocks that Outperform the S&P 500. Barclays lifted its price target on Johnson & Johnson (NYSE:JNJ) to $197 from $176 on December 2 ...
Johnson & Johnson trades above 21x forward EPS with $24B in Q3 revenue, and a raised FY25 sales guidance outlook. Read why JNJ stock is downgraded to hold.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results